ORIC News and Press, Oric Pharmaceuticals Inc. From 03/12/24

2024-03-12 14:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for ORIC on March 12, 2024 12:55PM ET. The previous analyst recommendation was Outperform. ORIC was trading at $14.62 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2024-03-12 14:00:02 ET David Nierengarten from Wedbush issued a price target of $20.00 for ORIC on 2024-03-12 12:55:00. The adjusted price target was set to $20.00. At the time of the announcement, ORIC was trading at $14.63. The overall price target consensus is at $7.0...

2024-03-11 17:01:32 ET More on ORIC Pharmaceuticals Cantor starts ORIC at overweight, cites potential of ORIC-114 ORIC Pharmaceuticals stock rises after it announces $125M private placement Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals Historica...

Presented initial Phase 1b data from three clinical programs that support potential best in class profiles, with ORIC-944 and ORIC-114 prioritized for further advancement towards registrational studies Initiation of combination study of ORIC-944 with AR inhibitor(s) in metastatic prostate...

2024-03-10 13:08:00 ET More on ALX Oncology, Bicycle Therapeutics, etc. Immunocore Holdings plc (IMCR) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q4 2023 Earnings Call Transcript Kura Oncology, Inc. 2023 Q4 - Results - Earnings Call Presentation ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will present a company ove...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that multiple abstracts have been accepted...

ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is the focus of IBN's latest stock spotlight. The company's shares have moved 11.46% on the day to $14.2. ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. The company's p...

2024-02-23 16:23:17 ET More on ORIC Pharmaceuticals ORIC Pharma NSCLC Brain Metastasis Data Is Highly Interesting ORIC Pharmaceuticals stock rises after it announces $125M private placement Seeking Alpha’s Quant Rating on ORIC Pharmaceuticals Historica...

SOUTH SAN FRANCISCO and SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat...